Cysteine-rich Whey Protein for Post COVID-19 Cognitive Impairment

This study focuses on finding ways to help people who have recovered from COVID-19 but are now facing issues with memory and thinking, known as cognitive impairment. The trial takes place in Cali, Colombia, and involves adults who have mild to moderate difficulties with cognition after COVID-19 but did not previously use the supplement Immunocal. By testing the effects of a cysteine-rich whey protein isolate called Immunocal, along with a structured neuropsychological rehabilitation program, the research aims to improve cognitive functioning in these individuals. This study is important because it could offer new therapies to help individuals regain their cognitive health after COVID-19. Participants in this study are divided into three groups: one receiving Immunocal supplementation, another undergoing neuropsychological rehabilitation, and a control group receiving no treatment. Immunocal is taken daily for 12 weeks by mixing and consuming the supplement. The effectiveness of these interventions is measured through cognitive tests that evaluate attention, memory, and other mental functions, as well as a physical test assessing lower body strength and endurance. These assessments help determine how well the interventions work in improving cognitive and physical health. Participants' symptoms and overall health are also monitored by doctors throughout the study to ensure safety and gather comprehensive health data.